727 related articles for article (PubMed ID: 29266249)
21. Age-related resistance to experimental autoimmune myasthenia gravis in rats.
Graus YM; Verschuuren JJ; Spaans F; Jennekens F; van Breda Vriesman PJ; De Baets MH
J Immunol; 1993 May; 150(9):4093-103. PubMed ID: 8386206
[TBL] [Abstract][Full Text] [Related]
22. Eculizumab: A Review in Generalized Myasthenia Gravis.
Dhillon S
Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
[TBL] [Abstract][Full Text] [Related]
23. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.
Lennon VA; Seybold ME; Lindstrom JM; Cochrane C; Ulevitch R
J Exp Med; 1978 Apr; 147(4):973-83. PubMed ID: 206648
[TBL] [Abstract][Full Text] [Related]
24. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
[TBL] [Abstract][Full Text] [Related]
25. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
[TBL] [Abstract][Full Text] [Related]
27. Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice.
Theissen L; Schroeter CB; Huntemann N; Räuber S; Dobelmann V; Cengiz D; Herrmann A; Koch-Hölsken K; Gerdes N; Hu H; Mourikis P; Polzin A; Kelm M; Hartung HP; Meuth SG; Nelke C; Ruck T
Cells; 2024 Mar; 13(6):. PubMed ID: 38534352
[TBL] [Abstract][Full Text] [Related]
28. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis.
Huijbers MG; Lipka AF; Plomp JJ; Niks EH; van der Maarel SM; Verschuuren JJ
J Intern Med; 2014 Jan; 275(1):12-26. PubMed ID: 24215230
[TBL] [Abstract][Full Text] [Related]
29. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.
Shen C; Lu Y; Zhang B; Figueiredo D; Bean J; Jung J; Wu H; Barik A; Yin DM; Xiong WC; Mei L
J Clin Invest; 2013 Dec; 123(12):5190-202. PubMed ID: 24200689
[TBL] [Abstract][Full Text] [Related]
30. Complement and cytokine based therapeutic strategies in myasthenia gravis.
Tüzün E; Huda R; Christadoss P
J Autoimmun; 2011 Sep; 37(2):136-43. PubMed ID: 21636248
[TBL] [Abstract][Full Text] [Related]
31. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.
Lindstrom JM; Einarson BL; Lennon VA; Seybold ME
J Exp Med; 1976 Sep; 144(3):726-38. PubMed ID: 182896
[TBL] [Abstract][Full Text] [Related]
32. Experimental autoimmune myasthenia gravis in the mouse.
Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
Curr Protoc Immunol; 2011 Nov; Chapter 15():Unit 15.23. PubMed ID: 22048803
[TBL] [Abstract][Full Text] [Related]
33. Experimental autoimmune myasthenia gravis.
Lindstrom J
J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):568-76. PubMed ID: 6249892
[TBL] [Abstract][Full Text] [Related]
34. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
35. Complement Inhibitor Therapy for Myasthenia Gravis.
Albazli K; Kaminski HJ; Howard JF
Front Immunol; 2020; 11():917. PubMed ID: 32582144
[TBL] [Abstract][Full Text] [Related]
36. Temporal correlation between serum CH
Yanagidaira M; Nishida Y; Yokota T
Clin Neurol Neurosurg; 2020 Feb; 189():105630. PubMed ID: 31830679
[TBL] [Abstract][Full Text] [Related]
37. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
38. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.
Mori S; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Hotta H; Desaki J; Kishi M; Konishi T; Nishino Y; Miyazawa A; Maruyama N; Shigemoto K
Am J Pathol; 2012 Feb; 180(2):798-810. PubMed ID: 22142810
[TBL] [Abstract][Full Text] [Related]
39. Myasthenia gravis and the neuromuscular junction.
Querol L; Illa I
Curr Opin Neurol; 2013 Oct; 26(5):459-65. PubMed ID: 23945282
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
Martínez-Martínez P; Losen M; Duimel H; Frederik P; Spaans F; Molenaar P; Vincent A; De Baets MH
Am J Pathol; 2007 Feb; 170(2):644-57. PubMed ID: 17255332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]